|
License Anticipated to Aid the Development of DNA Vaccines for Chronic Infectious Diseases and Cancer
SAN DIEGO, CA, USA | May 27, 2008 | Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that it has entered into a license agreement with Advanced BioScience Laboratories, Inc. (ABL) so that ABL may provide advanced electroporation delivery of DNA vaccines for its research uses. The license will permit ABL, based in Kensington, Maryland, to conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines as a service for its research customers. Inovio will receive a royalty on such services.
Phil Markham, Ph.D., Scientific Director of ABL, said: "We have used electroporation, like the results being produced using this technology, and feel it is an important tool in vaccine development. Clients have been requesting electroporation technology and we look forward to being able to provide this cutting edge tool and expertise as a service for customers."
Avtar Dhillon, MD, president and CEO of Inovio, said: "We are pleased to enter into a license agreement with ABL, one of the leading providers of contract vaccine development services for the US government. We believe this license may help enable the early development of a number of vaccines designed to elicit strong T-cell responses, which are thought to be needed to control a number of chronic infectious diseases, such as HIV and cancer."
About Advanced BioScience Laboratories, Inc.
ABL is dedicated to conducting research and providing resources to develop and evaluate vaccines, therapeutics and diagnostics for infectious agents for the biomedical community. ABL is a highly skilled contract research organization (CRO) having extensive experience working with government, commercial, and other groups. ABL is committed to delivering quality services that advance HIV and infectious disease research for the public good. ABL can help with all aspects of product development including; basic research, vaccine or product design, animal models to include immunomonitoring, cGMP manufacturing of biologics for phase I and II clinical trials, and many other services. To find out more about ABL, please visit the company's website at www.ablinc.com.
About Inovio Biomedical Corporation
Inovio Biomedical (AMEX: INO) is focused on developing multiple DNA-based immunotherapies and DNA vaccines. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Human data has shown that Inovio's electroporation-based DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.
SOURCE: Inovio Biomedical Corporation |
